1. Israel Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Hadasit Bio-Holdings Ltd

Hadasit Bio-Holdings Ltd

HSITF
Hadasit Bio-Holdings LtdUS flagOther OTC
0.12
USD
- -
- -
1.33MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
0.03
0.02
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-5.37
-5.78
-2.14
-4.46
-0.22
1.2
-0.03
-2.02
2.82
2.56
-2.77
-2.6
-0.31
-0.67
Free Cash Flow per Basic Share
-6.57
-4.55
-4.16
-3.56
-2.08
-1.62
-1.53
-0.29
-0.36
-0.19
-0.19
-0.18
-0.15
-5.97
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
0.59
- -
- -
- -
- -
- -
- -
Book Value per Share
-43.34
-38
-35.8
-32.09
-16.54
-9.68
-9.62
-11.63
-8.81
-6.22
-9.03
-11.74
-12.06
-49.02
Tangible Book Value per Share
16.97
8.97
2.73
14.45
7.68
5.52
3.11
0.5
3.36
5.92
3.16
0.47
0.15
22.76
Basic Weighted Avg Shares
2
3
3
4
7
11
11
11
11
11
11
11
11
2
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
-1,051.67
-1,217.2
-26,191.3
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-11
-15
-6
-17
-2
13
- -
-22
31
28
-31
-29
-3
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
3,659.44
-126.4
-96,934.78
- -
- -
- -
- -
- -
- -
Working Capital
25
18
9
56
43
51
17
- -
35
24
14
6
2
43
LT Debt
- -
- -
1
1
- -
- -
- -
- -
1
- -
1
- -
- -
- -
Total Equity
36
25
22
60
62
61
34
6
37
66
35
5
2
62
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-6.02
- -
- -
-10.01
-3.92
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
-42.68
- -
- -
-28.11
-35.21
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'16
Sep'16
Dec'16
ST Debt
- -
1
2
LT Borrowings
1
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
11
Market Capitalization
2
3
3

Working Capital

FRC

•

in mil. unless spec.
Jun'16
Sep'16
Dec'16
Total Current Assets
47
38
48
Cash, Cash Equivalents & STI
20
12
46
Accounts Receivable, Net
2
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
4
4
Payables & Accruals
- -
- -
- -
ST Debt
- -
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
49.79%
90.37%
-67.88%
Free Cash Flow
-9.03%
-8.65%
-14.86%
Net Income, GAAP
546.66%
-110.35%
-87.99%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-2.6
2024
- -
- -
- -
- -
-0.31
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

MCPAPIChat
CEO
Yuval Adar
Full Time Employees
2
Sector
Healthcare
Industry
Biotechnology
Address
Jerusalem Bio-Park Jerusalem Israel 91120
IPO Date
Oct 27, 2010
Website
hbl.co.il
Similar Companies
JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS)
Tourmaline Bio, Inc. (TRML)
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)
Oyster Point Pharma, Inc. (OYST)
Jazz Pharmaceuticals plc (JAZZ)
Acumen Pharmaceuticals, Inc. (ABOS)
Business
Hadasit Bio-Holdings Ltd. (HBL) is a publicly traded biotechnology investment company that provides funding and support to early-stage pharmaceutical firms originating from intellectual property developed at Hadassah University Medical Center in Israel. Founded in 2005 and headquartered in Jerusalem, the company operates as a subsidiary of Hadasit Ltd., the technology transfer arm of Hadassah Medical Organization, with shares listed on the Tel Aviv Stock Exchange (TASE: HDST) and OTC markets (HSITF); it focuses on pre-clinical and early clinical-stage biotech ventures in oncology, ophthalmology, inflammatory diseases, and regenerative medicine. HBL's core portfolio includes stakes in KAHR Medical, which develops multifunctional immuno-recruitment protein (MIRP) therapies for immuno-oncology to unmask cancer cells and recruit immune responses; Enlivex Therapeutics (NASDAQ: ENLV), advancing off-the-shelf macrophage reprogramming cell therapies like Allocetra for solid cancers, sepsis, and acute inflammatory conditions; and CellCure Neurosciences (a Lineage Cell Therapeutics subsidiary), specializing in human embryonic stem cell-derived OpRegen RPE cell therapy for dry age-related macular degeneration and other ocular disorders, which entered an exclusive worldwide collaboration with Roche/Genentech in December 2021 for development and commercialization. The company targets high-potential blockbuster drugs by distributing investment risk across its portfolio, primarily serving global pharmaceutical markets through minority to partial ownership positions. Recent developments include ongoing portfolio advancements such as Enlivex's multicenter Phase I/II trial approvals for Allocetra and KAHR's prior $46.5 million financing in 2021 to expand its immunotherapeutic pipeline, alongside Hadasit parent-level partnerships like the July 2025 alliance with TechsoMed for AI-driven cancer image-guided therapies and June 2024 collaboration with Pangea Biomed and Ultima Genomics for solid tumor treatments at Hadassah's Sharett Cancer Institute.